Rituximab meets CLL endpoint

Biogen Idec (NASDAQ:BIIB), Genentech (NYSE:DNA) and Roche (SWX:ROG) said rituximab plus chemotherapy met the primary endpoint of a significant increase in progression-free survival (PFS) vs. chemotherapy alone in the open-label, international Phase III REACH trial in 552 patients with relapsed or refractory CD20-positive chronic lymphocytic leukemia (CLL). In January, the companies reported that the chimeric mAb against CD20 antigen met the primary endpoint of a significant increase in PFS vs. chemotherapy alone in the Phase III CLL8 trial to treat CLL. ...